STEMSY

Built to grow through acquisitions, and driven by an industry experienced management team, our company is creating a vertical group of businesses to grow, process, test, sell and deliver functional mushrooms, psilocybin R&D and medicinal CBD.

Stemsy Inc. was founded in 2006

A stated change of business to take advantage of the new in functional healthcare opportunities in 2021. The company has already identified the initial companies to purchase, and the model to grow and build those acquisitions in the medicinal CBD, functional mushroom and psilocybin space. The company is currently assessing and identifying future acquisitions. Stemsy is raising capital for the new acquisitions using the Regulation A exemption. ​ Sage Elie was brought on as CEO, in 2020, in preparation for the stated change in business, with his extensive knowledge and over 25 year’s experience in the cannabis market.

STEMSY'S SOLUTION   

We have developed a strategic plan and identified target acquisitions that will enable Stemsy to bring together complementary businesses that can deliver a vertically integrated solution in this exciting market. We target the phyto functional and forward medicinal market to create synergies and allow businesses to focus on what they do best and not try to be experts at everything. 

About Us

Since the legalization of Cannabis, there has been increasing research to back up the observed benefits of CBD, which has, in turn, increased awareness of the various health benefits. This has fuelled the worldwide market for Cannabidiol (CBD) which is expected to grow at a CAGR of roughly 32.0% over the next five years and will reach 1251.8 million USD in 2024, from 311.8 million USD in 2019, according to Research & Markets, Oct 2020. ​ According to Data Bridge Market Research, the psychedelic pharmaceutical market is projected to grow at a CAGR of 16.3% over the next eight years to reach $6.85 billion by 2027. The key factors that will fuel this growth include the increasing prevalence of depression and other mental health disorders in the U.S. and the growing acceptance of psychedelic pharmaceuticals to treat depression. ​ But the challenge is the fragmented nature of the market.

An umbrella company targeting the phyto functional and forward medicinal market

.

1
PSILOCYBIN

Research has shown it has potential to treat a range of psychiatric and behavioural disorders, including: ​ - Depression - Obsessive Compulsive Disorder Quitting Smoking - Alcohol Addiction - Cocaine Addiction - Cluster Headaches - Cancer-related psychological distress End of Life psychological distress   Much like Cannabis was perceived in the general public, Mushrooms ‘shrooms, which contain the active ingredient psilocybin, are following a similar trajectory from the psychedelic 60s to legalized medicinal drug. ​ Trials of psilocybin are taking place across North America. Initiatives have taken place in Denver, Colorado and Oregon to legalize psilocybin mushrooms. Clinics have opened up across Canada to treat patients with psilocybin, with Health Canada granting exemptions to patients for its use. 

2
CBD

Since the legalization of Cannabis, there has been increasing research to back up the observed benefits of CBD, which has, in turn, increased awareness of the various health benefits. This has fuelled the worldwide market for Cannabidiol (CBD) which is expected to grow at a CAGR of roughly 32.0% over the next five years and will reach 1251.8 million USD in 2024, from 311.8 million USD in 2019, according to Research & Markets, Oct 2020. ​ According to Data Bridge Market Research, the psychedelic pharmaceutical market is projected to grow at a CAGR of 16.3% over the next eight years to reach $6.85 billion by 2027. The key factors that will fuel this growth include the increasing prevalence of depression and other mental health disorders in the U.S. and the growing acceptance of psychedelic pharmaceuticals to treat depression.  

Our Management Team

Extensive Industry Experience

Grow
Process
Deliver